Thermo Fisher Scientific Stock Rockets 9.1% With 9-Day Winning Streak
Thermo Fisher Scientific (TMO) stock hit day 9 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 9.1% return. The company has gained about $18 Bil in value over the last 9 days, with its current market capitalization at about $216 Bil. The stock remains 10.4% above its value at the end of 2024. This compares with year-to-date returns of 15.5% for the S&P 500.
TMO provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products worldwide for research, drug production, diagnostics, and laboratory equipment needs. After this rally, is TMO still a buy – or is it time to lock in gains? Deep dive with Buy or Sell TMO.
A single stock can be risky, but there is a huge value to a broader, diversified approach we take with the Trefis High Quality Portfolio. That is one way to look at stocks. The Trefis High Quality Portfolio evaluates much more, and is designed to reduce stock-specific risk while giving upside exposure.
Comparing TMO Stock Returns With The S&P 500
The following table summarizes the return for TMO stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | TMO | S&P 500 |
|---|---|---|
| 1D | 0.1% | 0.8% |
| 9D (Current Streak) | 9.1% | 2.1% |
| 1M (21D) | 24.7% | 2.8% |
| 3M (63D) | 18.2% | 6.3% |
| YTD 2025 | 10.4% | 15.5% |
| 2024 | -1.7% | 23.3% |
| 2023 | -3.4% | 24.2% |
| 2022 | -17.3% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 37 S&P constituents with 3 days or more of consecutive gains and 51 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 21 | 33 |
| 4D | 4 | 14 |
| 5D | 2 | 4 |
| 6D | 6 | 0 |
| 7D or more | 4 | 0 |
| Total >=3 D | 37 | 51 |
Key Financials for Thermo Fisher Scientific (TMO)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $42.9 Bil | $42.9 Bil |
| Operating Income | $7.3 Bil | $7.7 Bil |
| Net Income | $6.0 Bil | $6.3 Bil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $10.4 Bil | $10.9 Bil |
| Operating Income | $1.8 Bil | $1.9 Bil |
| Net Income | $1.5 Bil | $1.6 Bil |
While TMO stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.